FATE THERAPEUTICS INC Increase (Decrease) in Accounts Receivable
FATE THERAPEUTICS INC (FATE) reported Increase (Decrease) in Accounts Receivable of -$213.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-13
- FATE THERAPEUTICS INC increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$1.00K.
- FATE THERAPEUTICS INC increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$212.00K.
- FATE THERAPEUTICS INC increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $233.00K.
- FATE THERAPEUTICS INC increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$713.00K, a 128.76% decline year-over-year.
- FATE THERAPEUTICS INC increase (decrease) in accounts receivable for fiscal 2025 was -$2.62M, a 335.76% decline from fiscal 2024.
- FATE THERAPEUTICS INC increase (decrease) in accounts receivable for fiscal 2024 was $1.11M.
- FATE THERAPEUTICS INC increase (decrease) in accounts receivable for fiscal 2023 was -$36.65M, a 222.98% decline from fiscal 2022.
- FATE THERAPEUTICS INC increase (decrease) in accounts receivable for fiscal 2022 was $29.80M, a 843.16% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$213.00K 10-Q · filed 2026-08-13 | $20.00K derived: sum of 3 quarters · filed 2026-08-13 | -$693.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$212.00K 10-Q · filed 2026-05-13 | $21.00K derived: sum of 2 quarters · filed 2026-05-13 | -$692.00K derived: sum of 3 quarters · filed 2026-05-13 | -$1.70M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $233.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$480.00K derived: sum of 2 quarters · filed 2026-02-26 | -$1.49M derived: sum of 3 quarters · filed 2026-08-13 | -$2.62M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$713.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$1.72M derived: sum of 2 quarters · filed 2026-08-13 | -$2.86M 10-Q · filed 2025-11-13 | -$3.44M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.14M 10-Q · filed 2026-08-13 | -$2.73M derived: sum of 3 quarters · filed 2026-08-13 | -$253.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$1.13M 10-Q · filed 2026-05-13 | -$1.72M derived: sum of 2 quarters · filed 2026-05-13 | $757.00K derived: sum of 3 quarters · filed 2026-05-13 | $947.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$588.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.89M derived: sum of 2 quarters · filed 2026-02-26 | $2.08M derived: sum of 3 quarters · filed 2026-02-26 | $1.11M 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.67M derived: sum of 2 quarters · filed 2025-11-13 | $1.70M 10-Q · filed 2025-11-13 | $1.99M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $190.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$778.00K 10-Q · filed 2025-08-12 | -$490.00K derived: sum of 3 quarters · filed 2025-08-12 | -$1.79M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$968.00K 10-Q · filed 2025-05-13 | -$680.00K derived: sum of 2 quarters · filed 2025-05-13 | -$1.98M derived: sum of 3 quarters · filed 2025-05-13 | -$12.64M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $288.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$1.01M derived: sum of 2 quarters · filed 2025-03-05 | -$11.67M derived: sum of 3 quarters · filed 2025-03-05 | -$36.65M 10-K · filed 2025-03-05 |
| 2023-09-30 | -$1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$11.96M derived: sum of 2 quarters · filed 2024-11-12 | -$36.94M 10-Q · filed 2024-11-12 | -$8.69M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$10.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$35.65M 10-Q · filed 2024-08-13 | -$7.39M derived: sum of 3 quarters · filed 2024-08-13 | -$10.29M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$24.98M 10-Q · filed 2024-05-09 | $3.28M derived: sum of 2 quarters · filed 2024-05-09 | $374.00K derived: sum of 3 quarters · filed 2024-05-09 | -$350.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $28.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $25.35M derived: sum of 2 quarters · filed 2024-02-26 | $24.63M derived: sum of 3 quarters · filed 2024-02-26 | $29.80M 10-K · filed 2024-02-26 |
| 2022-09-30 | -$2.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$3.63M derived: sum of 2 quarters · filed 2023-11-08 | $1.55M 10-Q · filed 2023-11-08 | $2.91M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$724.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $4.45M 10-Q · filed 2023-08-08 | $5.82M derived: sum of 3 quarters · filed 2023-08-08 | $2.82M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $5.17M 10-Q · filed 2023-05-03 | $6.54M derived: sum of 2 quarters · filed 2023-05-03 | $3.55M derived: sum of 3 quarters · filed 2023-05-03 | $6.90M derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$1.63M derived: sum of 2 quarters · filed 2023-02-28 | $1.73M derived: sum of 3 quarters · filed 2023-02-28 | $3.16M 10-K · filed 2023-02-28 |
| 2021-09-30 | -$2.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $365.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.79M 10-Q · filed 2022-11-03 | $4.07M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $3.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $4.79M 10-Q · filed 2022-08-03 | $7.06M derived: sum of 3 quarters · filed 2023-02-28 | $8.59M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $1.43M 10-Q · filed 2022-05-04 | $3.70M derived: sum of 2 quarters · filed 2023-02-28 | $5.23M derived: sum of 3 quarters · filed 2023-02-28 | |
| 2020-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $3.80M derived: sum of 2 quarters · filed 2023-02-28 | $5.51M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $1.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $3.24M 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $1.72M 10-Q · filed 2021-08-04 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | -$500.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$500.00K 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | -$500.00K 10-Q · filed 2020-08-05 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $500.00K 10-K · filed 2021-02-24 | ||
| 2018-09-30 | $500.00K 10-Q · filed 2019-11-05 | |||
| 2018-03-31 | $500.00K 10-Q · filed 2019-05-07 | |||
| 2015-09-30 | $846.00K 10-Q · filed 2016-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |